Key result
Admission hyperglycemia linked to ~269% higher incidence of no-reflow.
Why the study?
Hyperglycemia is associated with increased risks of heart failure, cardiogenic shock, and death after AMI, but its underlying mechanism remains unknown.
Does admission hyperglycemia increase the risk of the no-reflow phenomenon in patients with acute myocardial infarction?
Cohort (n=146)
Does admission hyperglycemia increase the risk of the no-reflow phenomenon in patients with acute myocardial infarction?
Admission hyperglycemia in patients with acute myocardial infarction is independently associated with the no-reflow phenomenon, larger infarct size, and worse functional recovery.
OBJECTIVES: We investigated the association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction (AMI). BACKGROUND: Hyperglycemia is associated with increased risks of heart failure, cardiogenic shock, and death after AMI, but its underlying mechanism remains unknown. METHODS: A total of 146 consecutive patients with a first AMI were studied by intracoronary myocardial contrast echocardiography (MCE) after successful reperfusion within 24 h after symptom onset. Two-dimensional echocardiography was recorded on day 1 and three months later to determine the change in the wall motion score (DeltaWMS; sum of 16 segmental scores; dyskinesia = 4 to normokinesia = 0). RESULTS: The no-reflow phenomenon was found on MCE in 49 (33.6%) of 146 patients; their glucose level on hospital admission was significantly higher than that of patients who did not exhibit this phenomenon (209 +/- 79 vs. 159 +/- 56 mg/dl; p < 0.0001). There was no difference in glycosylated hemoglobin or in the incidence of diabetes mellitus between the two subsets. The no-reflow phenomenon was more often observed in the 75 patients with hyperglycemia (>/=160 mg/dl) than in those without hyperglycemia (52.0% vs. 14.1%; p < 0.0001). Patients with hyperglycemia had a higher peak creatine kinase level (2,497 +/- 1,603 vs. 1,804 +/- 1,300 IU/l; p = 0.005) and a lower DeltaWMS (3.7 +/- 4.8 vs. 5.7 +/- 4.3; p = 0.01) than did those without hyperglycemia. The blood glucose level was an independent prognostic factor for no reflow, along with age, gender, absence of pre-infarction angina, complete occlusion of the culprit lesion, and anterior AMI. CONCLUSIONS: Hyperglycemia might be associated with impaired microvascular function after AMI, resulting in a larger infarct size and worse functional recovery.
No takes yet. Share an insight, caveat, or question.
Iwakura et al. (2002) conducted a cohort in acute myocardial infarction (n=146). Hyperglycemia (≥160 mg/dl) vs. Without hyperglycemia was evaluated on No-reflow phenomenon on intracoronary myocardial contrast echocardiography (p=<0.0001). Hyperglycemia on admission was associated with a significantly higher incidence of the no-reflow phenomenon compared to patients without hyperglycemia (52.0% vs. 14.1%; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: